Complement Factor D Deficiency

mutation in CFD

Also Known As:

Factor D Deficiency

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Disease Context: Research Results

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 933
- Inborn Genetic Diseases: 11939
  - Primary Immunodeficiency Diseases: 1189
    - Hereditary Complement Deficiency Diseases: 254
      - Complement Factor D Deficiency: 7
Immune System Diseases: 4321
- Membranoproliferative Glomerulonephritis: 1224
  - Complement Factor D Deficiency: 7
- Immunologic Deficiency Syndromes: 91
  - Primary Immunodeficiency Diseases: 1189
    - Hereditary Complement Deficiency Diseases: 254
      - Complement Factor D Deficiency: 7
Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Peptide Hydrolases: 23957
      - Serine Proteases: 3726
        Serine Endopeptidases: 11
        Complement Factor D: 303
        Complement Factor D Deficiency: 7
      - Endopeptidases: 633
        Serine Endopeptidases: 11
        Complement Factor D: 303
        Complement Factor D Deficiency: 7
    - Complement Activating Enzymes
      - Complement Factor D: 303
        Complement Factor D Deficiency: 7
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Immunoproteins: 43
      - Complement System Proteins: 33379
        Complement Activating Enzymes
        Complement Factor D: 303
        Complement Factor D Deficiency: 7
Urogenital Diseases: 126

Related Diseases

1.	Inflammation (Inflammations)
2.	Meningococcal Infections
3.	HIV Infections (HIV Infection)
4.	Infections
5.	Glomerulonephritis

Experts

1.	Hiraoka, Yuichi: 1 article (10/2020)
2.	Osaka, Mizuko: 1 article (10/2020)
3.	Tsuru, Hiromi: 1 article (10/2020)
4.	Yoshida, Masayuki: 1 article (10/2020)
5.	Committee on Infectious Diseases: 1 article (12/2011)
6.	Abrera-Abeleda, M A: 1 article (06/2007)
7.	Pickering, M C: 1 article (06/2007)
8.	Sethi, S: 1 article (06/2007)
9.	Smith, R J H: 1 article (06/2007)
10.	Xu, Y: 1 article (06/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Complement Factor D Deficiency:

1.	LipidsIBA 10/16/2020 - "These data suggest that the Factor D deficiency improved hepatic lipid accumulation and hepatic inflammation in HFD-fed mice."
2.	Complement Factor D (Factor D)IBA 07/01/2001 - "The mode of inheritance of factor D deficiency is autosomal recessive, in accordance with the localization of the Factor D gene on chromosome 19. " 06/15/2006 - "Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections."
3.	ProperdinIBA 01/01/1993 - "In contrast, the strong association of properdin and factor D deficiency with serious infections caused by encapsulated Gram-negative bacteria suggests a more immediate involvement of the alternative pathway in a specific segment of immunity and its pathology. " 12/01/2011 - "This review prompted the following recommendations: (1) adolescents should be routinely immunized at 11 through 12 years of age and given a booster dose at 16 years of age; (2) adolescents who received their first dose at age 13 through 15 years should receive a booster at age 16 through 18 years or up to 5 years after their first dose; (3) adolescents who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose; (4) a 2-dose primary series should be administered 2 months apart for those who are at increased risk of invasive meningococcal disease because of persistent complement component (eg, C5-C9, properdin, factor H, or factor D) deficiency (9 months through 54 years of age) or functional or anatomic asplenia (2-54 years of age) and for adolescents with HIV infection; and (5) a booster dose should be given 3 years after the primary series if the primary 2-dose series was given from 2 through 6 years of age and every 5 years for persons whose 2-dose primary series or booster dose was given at 7 years of age or older who are at risk of invasive meningococcal disease because of persistent component (eg, C5-C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia."
4.	Conjugate VaccinesIBA 12/01/2011 - "This review prompted the following recommendations: (1) adolescents should be routinely immunized at 11 through 12 years of age and given a booster dose at 16 years of age; (2) adolescents who received their first dose at age 13 through 15 years should receive a booster at age 16 through 18 years or up to 5 years after their first dose; (3) adolescents who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose; (4) a 2-dose primary series should be administered 2 months apart for those who are at increased risk of invasive meningococcal disease because of persistent complement component (eg, C5-C9, properdin, factor H, or factor D) deficiency (9 months through 54 years of age) or functional or anatomic asplenia (2-54 years of age) and for adolescents with HIV infection; and (5) a booster dose should be given 3 years after the primary series if the primary 2-dose series was given from 2 through 6 years of age and every 5 years for persons whose 2-dose primary series or booster dose was given at 7 years of age or older who are at risk of invasive meningococcal disease because of persistent component (eg, C5-C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia."
5.	Complement Factor H (Factor H)IBA 12/01/2011 - "This review prompted the following recommendations: (1) adolescents should be routinely immunized at 11 through 12 years of age and given a booster dose at 16 years of age; (2) adolescents who received their first dose at age 13 through 15 years should receive a booster at age 16 through 18 years or up to 5 years after their first dose; (3) adolescents who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose; (4) a 2-dose primary series should be administered 2 months apart for those who are at increased risk of invasive meningococcal disease because of persistent complement component (eg, C5-C9, properdin, factor H, or factor D) deficiency (9 months through 54 years of age) or functional or anatomic asplenia (2-54 years of age) and for adolescents with HIV infection; and (5) a booster dose should be given 3 years after the primary series if the primary 2-dose series was given from 2 through 6 years of age and every 5 years for persons whose 2-dose primary series or booster dose was given at 7 years of age or older who are at risk of invasive meningococcal disease because of persistent component (eg, C5-C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia."
6.	Thromboplastin (Tissue Factor)IBA 10/01/1958 - "Deletion of plasma thromboplastin factor D deficiency."
7.	Fatty Acids (Saturated Fatty Acids)IBA 10/16/2020 - "Factor D deficiency downregulated expression of genes related to fatty acid uptake and de novo lipogenesis in the liver. "
8.	Complement System Proteins (Complement)IBA 12/01/2011 - "This review prompted the following recommendations: (1) adolescents should be routinely immunized at 11 through 12 years of age and given a booster dose at 16 years of age; (2) adolescents who received their first dose at age 13 through 15 years should receive a booster at age 16 through 18 years or up to 5 years after their first dose; (3) adolescents who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose; (4) a 2-dose primary series should be administered 2 months apart for those who are at increased risk of invasive meningococcal disease because of persistent complement component (eg, C5-C9, properdin, factor H, or factor D) deficiency (9 months through 54 years of age) or functional or anatomic asplenia (2-54 years of age) and for adolescents with HIV infection; and (5) a booster dose should be given 3 years after the primary series if the primary 2-dose series was given from 2 through 6 years of age and every 5 years for persons whose 2-dose primary series or booster dose was given at 7 years of age or older who are at risk of invasive meningococcal disease because of persistent component (eg, C5-C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia."
9.	Antigen-Antibody Complex (Immune Complex)IBA 06/01/2007 - "Mesangial immune complex glomerulonephritis due to complement factor D deficiency."
10.	A-factor (Streptomyces)IBA 06/15/2006 - "In conclusion, this is the second report of a factor D gene mutation leading to factor D deficiency in a family with meningococcal disease. "